Thrivent Financial for Lutherans Has $5.62 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Thrivent Financial for Lutherans raised its position in Glaukos Co. (NYSE:GKOS) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,152 shares of the medical instruments supplier’s stock after acquiring an additional 1,339 shares during the period. Thrivent Financial for Lutherans owned about 0.08% of Glaukos worth $5,622,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Point72 Asset Management L.P. bought a new stake in Glaukos in the second quarter valued at about $67,460,000. Primecap Management Co. CA grew its stake in shares of Glaukos by 43.9% in the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after purchasing an additional 372,180 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos by 148.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock worth $48,805,000 after buying an additional 246,322 shares during the period. Iron Triangle Partners LP boosted its stake in Glaukos by 75.6% in the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after buying an additional 184,919 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its position in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock valued at $95,112,000 after acquiring an additional 155,653 shares during the period. Institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The trade was a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Glaukos Stock Up 2.3 %

Shares of GKOS opened at $144.00 on Friday. The business’s fifty day moving average price is $132.40 and its two-hundred day moving average price is $123.58. The firm has a market capitalization of $7.94 billion, a price-to-earnings ratio of -47.68 and a beta of 1.02. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $146.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.50) earnings per share. On average, analysts predict that Glaukos Co. will post -1.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of analyst reports. Stifel Nicolaus lifted their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Piper Sandler set a $140.00 price target on shares of Glaukos in a report on Thursday, October 17th. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Needham & Company LLC lifted their target price on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Truist Financial increased their price target on Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $134.55.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.